Test with Guardant360 first
Take action on more of your patients

Guardant360-first paradigm tests more biomarkers for more patients, faster

Patient Advantages

MORE PATIENTS
3x more patients tested for guideline-recommended biomarkers* vs tissue testing

FASTER RESULTS
1 week faster than tissue

>90% concordance to tissue

Time to results

Testing for the 4 biomarkers with FDA-approved therapies

95% of patients
31% of patients

7 days from sample receipt to results
15 days

Standard-of-care tissue testing

GUARDANT®

For your next patient with newly diagnosed advanced NSCLC, how will you test for the guideline-recommended biomarkers to guide your treatment decision?

Contact your Guardant360 Representative to order Guardant360 for your next patient with NSCLC

855.698.8887
clientservices@guardanthealth.com

www.Guardant360.com

©2019 Guardant Health, Inc
All rights reserved. March 2019
505 Penobscot Drive
Redwood City, CA 94063

NILE: a large prospective study comparing the Guardant360® assay vs standard-of-care tissue testing for guideline-recommended biomarker detection in newly diagnosed advanced NSCLC

More patients tested
More biomarkers detected
Faster results

NILE establishes a Guardant360-first paradigm that solves the issues of undergenotyping and treatment delays associated with tissue testing


REC-MKT-000077 R1
NILE met its primary endpoint: Guardant360 as effective as standard-of-care tissue testing in detecting NSCLC biomarkers

Guardant360 tests more patients, faster

NILE is the largest head-to-head, prospective study of Guardant360 vs standard-of-care tissue testing

Guardant360 (cfDNA)
Concurrently tested

Standard-of-care tissue testing
Concurrently tested based on physician’s choice (PCR, FISH, IHC, and/or NGS)

Guardant360 performed similarly to tissue in the detection of guideline-recommended biomarkers

concordance to tissue
Includes the 4 biomarkers with FDA-approved therapies (EGFR, ALK, ROS1, BRAF)

greater than 90%

Tissue misses guideline-recommended biomarkers
In patients who had complete results from both tissue and liquid tests, each testing method missed ~15% of what the other found

Guardant360 enabled more complete biomarker assessment than tissue testing

Guardant360 tested 95% of patients

Guardant360 tested
95% of patients
for the 4 biomarkers with FDA-approved therapies vs
31% with tissue

Faster test results and less time waiting to make treatment decisions
Guardant360 provided test results in 9 days vs 15 for tissue

1 week faster with Guardant360

Guardant360-first testing finds more patients than tissue-first testing

Guardant360-first
87% of patients with biomarkers detected

Tissue first
67% of patients with biomarkers detected

20% more patients with biomarkers detected with Guardant360-first testing

Newly diagnosed patients with advanced NSCLC (N=282)